This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sandbox Reserved 433
From Proteopedia
(Difference between revisions)
(Quiz question 1) |
|||
| Line 23: | Line 23: | ||
6. Lead previous section (effects of varying amounts and interactions) into diseases caused by GSK-3. Talk about potential therapeutic uses of it and new treatments under research. | 6. Lead previous section (effects of varying amounts and interactions) into diseases caused by GSK-3. Talk about potential therapeutic uses of it and new treatments under research. | ||
| - | + | Green Screen Caption: Show GSK-3 alpha and GSK-3 beta (if possible?) | |
==Overall Structure== | ==Overall Structure== | ||
| - | + | -GSK-3beta has the typical two-domain kinase fold with a beta strand domain at the N-terminal end and an alpha-helical domain at the C-terminal end | |
| + | -The ATP-binding site is at the interface of the alpha-helical and beta-strand domain and is bordered by the glycine-rich loop and the hinge | ||
| + | -The activation loop runs along the surface of the substrate binding groove | ||
| + | -The C-terminal residues are outside the core kinase fold and form a small domain that packs against the alpha-helical domain | ||
| - | <scene name='48/483890/ | + | -The beta-strand domain consists of seven antiparallel beta-strands |
| + | |||
| + | -Two phosphorylation sites that influence the catalytic activity of the protein | ||
| + | |||
| + | Haar, Ernst ter., Coll, Joyce T., Austen, Douglas A., Hsiao, Hsun-Mei., Swenson, Lora., Jain, Jugnu. Structure of GSK3B reveals a primed phosphorylation mechanism. Vertex Pharmaceuticals Incoprporated, Cambridge MA. Nature Publishing Group, Vol 8 No 7. July 2001. | ||
| + | |||
| + | -Monomer | ||
| + | |||
| + | -Overall structures of the enzyme are similar to that of the apoenzyme | ||
| + | |||
| + | -The crystals contain two molecules of GSK-3beta in the asymmetric unit and the two molecules are treated as identical | ||
| + | |||
| + | -Glycogen Synthase Kinase-3 (GSK-3) is a serine/threonine protein kinase | ||
| + | |||
| + | -Both isoforms have a conserved N-terminal serine reside (S21 for alpha and S9 for beta) | ||
| + | |||
| + | -Phosphorylation of the N-terminal serine residue plays an important role for further activity | ||
| + | |||
| + | |||
| + | |||
| + | Mishra, Nibha et al. Structure based virtual screening of GSK-3beta: Importance of protein flexibility and induced fit, 2009. Bioorganic & Medicinal Chemistry Letters, 2009, Vol. 19 Iss. 19, pp. 5582-5585. Retreived from http://www.sciencedirect.com/science/article/pii/S0960894X09011780 | ||
| + | |||
| + | <scene name='48/483890/Sarahs_scene/2'>GSK_3beta Overall Structure</scene> | ||
==Binding Interactions== | ==Binding Interactions== | ||
| Line 67: | Line 92: | ||
==Quiz Question 1== | ==Quiz Question 1== | ||
| - | Which isoform of GSK-3 would work best for ___ function in ___ pathway? | ||
| - | What type of bonding would GSK-3B exhibit with Staurosporine? A | + | GSK3 beta has various inhibiters; one example is AMP-PMP. These inhibitors bind to the N-terminus of the ligand on the GSK3 complex, a result of the classical binding mechanism for a protein kinase. However, in the case of Staurosporine (another inhibitor), it is unable to classically bind to the N-terminus of the ligand on the GSK3 complex. This is because in a GSK3 complex with Staurosporine, the ligand in question has an incompatible angle at the N-terminus, thus failing to undergo classical binding. |
| + | |||
| + | What type of bonding would GSK-3B exhibit with Staurosporine? Which residue of GSK-3 beta forms this type of bond with Staurosporine? A green screen of the complex, as well as a lewis structure of the Staurosporine molecule are found below, if needed. | ||
http://upload.wikimedia.org/wikipedia/commons/3/34/Staurosporine1.png | http://upload.wikimedia.org/wikipedia/commons/3/34/Staurosporine1.png | ||
| - | <scene name='48/483890/ | + | <scene name='48/483890/Ligand_bonding_type/1'>TextToBeDisplayed</scene> |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
==Quiz Question 2== | ==Quiz Question 2== | ||
What are the locations of the active sites with respect to the two isoforms? | What are the locations of the active sites with respect to the two isoforms? | ||
| - | These green screens may help you | + | These green screens may help you. |
| - | <scene name='48/483890/Isophorms/2'> | + | <scene name='48/483890/Isophorms/2'>Color representation of the two isophorms complexed with the Staurosporine ligands</scene> |
| - | <scene name='48/483890/N_to_c_chain_rainbow/4'> | + | <scene name='48/483890/N_to_c_chain_rainbow/4'>Amino and Carboxy chain termini</scene> |
{{Template:ColorKey_Amino2CarboxyRainbow}} | {{Template:ColorKey_Amino2CarboxyRainbow}} | ||
| - | Answer: At | + | Answer: At the N and C terminal lobes. |
J.A. Bertrand, S. Thieffine, A. Vulpetti, C. Cristiani, B. Valsasina, S. Knapp, H.M. Kalisz, M. Flocco, Structural Characterization of the GSK-3β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors, Journal of Molecular Biology, Volume 333, Issue 2, 17 October 2003, Pages 393-407, ISSN 0022-2836, http://dx.doi.org/10.1016/j.jmb.2003.08.031. | J.A. Bertrand, S. Thieffine, A. Vulpetti, C. Cristiani, B. Valsasina, S. Knapp, H.M. Kalisz, M. Flocco, Structural Characterization of the GSK-3β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors, Journal of Molecular Biology, Volume 333, Issue 2, 17 October 2003, Pages 393-407, ISSN 0022-2836, http://dx.doi.org/10.1016/j.jmb.2003.08.031. | ||
| Line 104: | Line 126: | ||
*[http://www.proteopedia.org/wiki/index.php/3pup Glycogen Synthase Kinase 3 beta (GSK3B) complexed with a ruthenium octasporine ligand (OS1)] | *[http://www.proteopedia.org/wiki/index.php/3pup Glycogen Synthase Kinase 3 beta (GSK3B) complexed with a ruthenium octasporine ligand (OS1)] | ||
| - | Works Cited | ||
| - | |||
| - | Haar, Ernst ter., Coll, Joyce T., Austen, Douglas A., Hsiao, Hsun-Mei., Swenson, Lora., Jain, Jugnu. Structure of GSK3B reveals a primed phosphorylation mechanism. Vertex Pharmaceuticals Incoprporated, Cambridge MA. Nature Publishing Group, Vol 8 No 7. July 2001. | ||
==Credits== | ==Credits== | ||
Revision as of 19:56, 2 April 2015
| This Sandbox is Reserved from January 19, 2016, through August 31, 2016 for use for Proteopedia Team Projects by the class Chemistry 423 Biochemistry for Chemists taught by Lynmarie K Thompson at University of Massachusetts Amherst, USA. This reservation includes Sandbox Reserved 425 through Sandbox Reserved 439. |
| |||||||||||
